Study explores link between maternal asthma and ASD development in children
According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 10% of children globally. ASD is theorised to …
Post
-
-
Pfizer and Astellas’ Xtandi improves OS as combination therapy
Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only …
-
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial
PDS Biotechnology has completed subject recruitment for stage one of its open-label Phase II trial, evaluating the systemic administration of …
-
The unsustainability of clinical trials and need for transformative change
With pressures only intensifying on clinical trials, there are major concerns that current models are inefficient and unsustainable. Insight from …
-
XyloCor doses first subject in Phase IIb trial of gene therapy candidate XC001
XyloCor Therapeutics has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial, to assess the gene therapy …
-
Modular manufacturing: The key to unlocking mRNA expansion?
The evolving mRNA landscape has been marked by rapid advancements and a broadening scope of applications, primarily driven by the …
-
Adapting to funding and operational hurdles in today’s clinical trials landscape
Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries, …
-
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II …
-
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by …
-
Rhythm’s stock climbs on encouraging Phase II obesity drug data
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index …
-
How to remain a top CDMO in ADC-led oncology
Contract development and manufacturing organisations (CDMOs) worldwide are facing a multitude of challenges, which are heightened considerably in oncology by …
-
Six challenges facing emerging biotechs and how to solve them
Handing over your molecule is a big step for emerging biotechs. The process of developing new drugs is complex and …
-
LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial
LEO Pharma has reported positive outcomes from the 16-week interim analysis of the randomised Phase IIIb ADHAND trial of fully …
-
FDA approves Purespring’s application for Phase I/II trial of IgAN treatment
The US Food and Drug Administration (FDA) has approved Purespring Therapeutics’ investigational new drug (IND) application for PS-002, allowing the …
-
CTO East Coast 2025: AI can speed up all parts of clinical trial ecosystem
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around …
